GlassScriptPhysician profile
Oben Ojong
NPI 1619416286
$4,260.40
in general payments reported to CMS, 2019-2025
25 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $576 · 2021: $380 · 2022: $698 · 2023: $1,161 · 2024: $219 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $869.01 | 2019-2025 | |
| Abbvie INC. | $805.61 | 2020-2025 | |
| Genzyme Corporation | $366.72 | 2019-2025 | |
| Galderma Laboratories, L.P. | $317.77 | 2019-2025 | Dysport, Aklief |
| E.R. Squibb & Sons, L.L.C. | $281.40 | 2023-2024 | Sotyktu |
| Convatec INC. | $275.58 | 2024-2025 | |
| Janssen Biotech, INC. | $160.47 | 2023-2024 | Tremfya |
| Allergan, INC. | $149.63 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.07 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $104.70 | 2020-2024 | Dupixent |
| Genentech USA, INC. | $99.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Lilly USA, LLC | $85.30 | 2022-2023 | Taltz |
| Leo Pharma INC. | $82.38 | 2019-2023 | Adbry |
| Vyne Pharmaceuticals INC. | $78.03 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.58 | 2023-2025 | |
| Incyte Corporation | $45.89 | 2021-2022 | |
| Dermavant Sciences, INC. | $43.90 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $42.73 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $28.73 | 2021 | |
| Biofrontera INC. | $25.12 | 2019-2021 | |
| Almirall LLC | $24.25 | 2020 | |
| Botanix Sb INC | $21.80 | 2025 | Sofdra |
| Amgen INC. | $21.63 | 2020 | |
| Epi Health, LLC | $19.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oben Ojong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.